The Genentech BioOncology® Co-pay Assistance Program for VENCLEXTA + rituximab
Talk to your patients about their financial concerns related to their prescribed Genentech treatment. Eligible patients pay as little as $5 per valid prescription of Genentech BioOncology® product(s),* subject to a maximum benefit of $25,000 for a 12-month period, with the Genentech BioOncology® Co-pay Assistance Program.
*For FDA-approved Genentech BioOncology® single and combination therapies.
BioOncology® logo is a registered trademark of Genentech,
The Access Solutions logo is a registered trademark of Genentech, Inc.